Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.



from The Medical News http://www.news-medical.net/news/20141229/Janssen-Gilead-to-jointly-develop-darunavir-based-single-tablet-regimen-for-HIV-treatment.aspx